Meeting
2015 ASCO Annual Meeting
Association of immune-related thyroid disorders with pembrolizumab (pembro, MK-3475) in patients (pts) with advanced melanoma treated in KEYNOTE-001.
Authors
Caroline Robert
Gustave Roussy, Villejuif, France
Caroline Robert , Anthony M Joshua , Richard Kefford , Richard Wayne Joseph , Jedd D. Wolchok , F. Stephen Hodi , Omid Hamid , Jeffrey S. Weber , Tara C. Gangadhar , Roxana Stefania Dronca , Amita Patnaik , Hassane M. Zarour , Wen-Jen Hwu , Peter Hersey , Adil Daud , Maxine Giannotti , Xiaoyun Nicole Li , Scot Ebbinghaus , Soonmo Peter Kang , Antoni Ribas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01295827
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9050)
DOI
10.1200/jco.2015.33.15_suppl.9050
Abstract #
9050
Poster Bd #
293
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of biomarker-driven early discontinuation of anti–PD-1 therapy in patients with advanced melanoma (PET-Stop): ECOG-ACRIN EA6192.
First Author: Geoffrey Thomas Gibney
Poster
2020 ASCO Virtual Scientific Program
Combination anti-PD-1 and ipilimumab (ipi) therapy in patients with advanced melanoma and pre-existing autoimmune disorders (AD).
First Author: Lauren Julia Brown
Poster
2020 ASCO Virtual Scientific Program
Landmark analysis of immunotherapy duration and disease free survival in advanced melanoma patients with a complete response.
First Author: Grayce N. Selig
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya